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Junjie Peng1,2†, Xinxiang Li1,2†, Ying Ding3, Debing Shi1, Hongbin Wu2 and Sanjun Cai1,2*Abstract
Background: Stage T1-2 rectal cancers are unlikely to have lymph node metastases and neoadjuvant therapy is not
routinely administered. Postoperative management is controversial if lymph node metastases are detected in the
resected specimen. We studied the outcomes of patients with pT1-2 node-positive rectal cancer in order to
determine whether adjuvant radiotherapy was beneficial.
Methods: We conducted a retrospective analysis of 284 patients with pathological T1-2 node-positive rectal cancer
from a single institution. Outcomes, including local recurrence (LR), distant metastasis (DM), disease free survival
(DFS) and overall survival (OS), were studied in patients with detailed TN staging and different adjuvant treatment
modalities.
Results: The overall 5-year LR, DM, DFS and OS rates for all patients were 12.5%, 32.9%, 36.4% and 76.8%, respectively.
Local control was inferior among patients who received no adjuvant therapy. Patients could be divided into three
risk subsets: Low-risk, T1N1; Intermediate-risk, T2N1 and T1N2; and High-risk, T2N2. The 5-year LR rates were 5.3%,
9.8% and 26.4%, respectively (p = 0.005). In High-risk patients, addition of radiotherapy achieved a 5-year LR rate of
9.1%, compared 34.8% without radiotherapy.
Conclusions: In our study, we provide the detailed outcomes and preliminary survival analysis in a relatively infrequent
subset of rectal cancer. Three risk subsets could be identified based on local control for pT1-2 node positive rectal
cancer. Postoperative treatment needs to be individualized for patients with pT1-2 node-positive rectal cancer.
Keywords: Rectal cancer, Radiotherapy, Local recurrence, Stage, PrognosisBackground
Neoadjuvant chemoradiotherapy (CRT) is recommended
for clinical T3N0 and node-positive rectal cancers based
on studies demonstrating a decrease in local recurrences
and associated morbidity [1-3]. When confined within the
muscularis propria layer (T1-2), rectal cancers are less
likely to have spread to regional lymph nodes and a con-
siderable proportion of patients will receive primary sur-
gery. Adjuvant treatment is appropriate when pathological
lymph nodes are detected in the resected specimen of T1-
2 tumors. Outcomes data for this small subset of patients
with pT1-2 node-positive rectal cancer mainly derives* Correspondence: caisanjun@gmail.com
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reproduction in any medium, provided the orfrom pooled analyses, in which the local control rate was
not adequately addressed [4,5]. Therefore, the optimal ad-
juvant treatment for patients with T1-2 node-positive rec-
tal cancer is still in question.
Our series, a retrospective study from a single institu-
tion, was designed to assess the outcomes of patients with
pT1-2 node-positive rectal cancer who underwent primary
surgery followed by adjuvant chemotherapy, CRT, or no
adjuvant therapy. Our principal objective was to deter-
mine the impact of adjuvant radiotherapy in subsets of pa-
tients with pT1-2 node-positive rectal cancers.Materials and methods
Patients and treatment modalities
This study was approved by the Fudan University Shanghai
Cancer Center Institutional Ethics Committee, and written
informed consent was obtained from the patient for the
publication of this report and any accompanying images.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rectal cancer were treated and included in an institutional
database at Fudan University Shanghai Cancer Center
between January 1993 and December 2009. The primary
site was considered to be in the rectum if the tumor was
located within 15 cm from the anal verge by digital exam-
ination or endoscopy. In this study, the 6th edition of the
American Joint Committee on Cancer’s (AJCC) Cancer
Staging Manual was used; [6] we were unable to define
N1c patients according to the AJCC 7th edition [7]. Based
on an institutional follow-up protocol, patients were evalu-
ated every 6 months for the first three years after surgery,
and each year thereafter. Serum carcinoembryonic antigen
(CEA), chest X-ray/computed tomography scanning, and
abdomen and pelvic ultrasound/CT scanning was typically
performed according to surgeons’ guidance.
Between September and December 2012, all surviving
patients were contacted by telephone or mail in addition
to their scheduled follow up to update records for the
database. Sixty-five cases were excluded: 56 cases (19.7%)
were lost to follow-up; 9 cases (3.2%) had received neoad-
juvant chemotherapy. Therefore, a total of 219 patients
(77.1%) with AJCC pT1-2 node-positive rectal cancers
were included in this analysis.
The patterns of care at the Fudan University prior to
2006 did not include pelvic MRI as a preoperative staging
technique or neoadjuvant CRT for middle and low rectal
cancers. Before 2006, patients with cT1-2 disease rarely re-
ceived preoperative treatment regardless of node status.
All patients in this study underwent primary total mesor-
ectal excision (TME) together with either abdominope-
rineal resection (APR) or anterior resection (AR) of mid
and low rectal cancers by colorectal surgeons. As a retro-
spective study, the regimens of adjuvant chemotherapy
varied, including 5-fluorouracil (5-Fu) based monotherapy
(5-Fu/leucovorin or capecitabine) and combined chemo-
therapy (FOLFOX4, mFOLFOX6 and XELOX regimens).
For patients receiving adjuvant CRT, 5-fluorouracil based
chemotherapy was delivered concurrently with radiation
therapy. According to institutional routine, post-operative
radiotherapy is the North American standard of care [8].
The total dose of radiation in our series was 45-55 Gy.
The standard fractionation is 45 Gy in 25 fractions to the
pelvis in 5 weeks with an optional reduced volume boost
of 5.4–9 Gy in 3–5 fractions to tumor bed. There were
two phases based on radiation technique application. Four
fields with block were used before 2002 and 3D conformal
therapy was applied afterwards.
Statistics
Local recurrence (LR) is defined as recurrent tumor at the
anastomosis, pelvic viscera, parietal pelvic structures and/
or presacral or sacral bone invasion, determined by physical
examination, endoscopy or imaging. Distant Metastases(DM) is defined as metastases at distant organs or struc-
tures (lymph nodes, etc.). The rate of LR or DM is the cu-
mulative actuarial incidence of local recurrence or distant
metastases. Disease-free survival is defined as the time to
local recurrence, or distant metastases, or death (which-
ever occurs first). For each event (LR, DM and death), the
time to event was calculated from the completion of sur-
gery to the occurrence of that event. The rates of LR, DM,
disease-free survival (DFS) and OS were computed using
the Kaplan–Meier method. Log-rank tests were performed
to compare differences among survival curves in uni-
variate analyses. The distributions of clinicopathological
characteristics among different treatment modalities were
assessed by Pearson chi-square tests in crosstab tables.
The Cox regression model was used in multivariate ana-
lyses, and hazard ratios were estimated with correspond-
ing 95% confidence intervals (95% CI). A p-value of < 0.05
was considered statistically significant.Results
Outcomes and prognostic factors
With a median follow-up of 38 months (range, 6–
204 months), the 5-year LR, DM, DFS and OS rates for all
patients were 12.5%, 32.9%, 63.6% and 76.8%, respectively.
Detailed clinicopathological characteristics and treatment
are listed in Table 1. Patients who received no adjuvant
treatment experienced the highest 5-year LR rate (23.5%);
similar local control was observed following adjuvant CT
or CRT for all the patients as a whole (LR rates of 11.2%
and 7.5%, respectively) (Figure 1). Patients’ clinicopatho-
logical characteristics and postoperative treatment were
included in univariate analyses comparing different out-
comes at 5 years after surgery. Type of surgery was related
to 5-year LR rate. N stage was the only variable that was
significantly associated with all patients’ outcomes: 5-year
LR, DM, DFS and OS rates (Table 1). Although numerical
differences were observed in the univariate analyses, pa-
tients who received adjuvant CRT did not show statisti-
cally improved local control compared to patients who
received CT only (5-year LR, 7.5% with CRT vs. 11.2%
with CT, p = 0.234).
Multivariate analyses revealed that N stage (N2 vs. N1)
was the only independent prognostic factor for 5-year DM,
DFS and OS rates, with hazard ratios of 2.12 (95% CI 1.17-
3.83, p = 0.013), 2.37 (95% CI 1.40-4.00, p = 0.001) and 2.89
(95% CI 1.44-5.81, p = 0.003), respectively. N stage (N2 vs.
N1) and type of surgery (APR vs. AR) were independent
prognostic factors for 5-year LR rate, with hazard ratios of
3.59 (95% CI 1.52-8.48, p = 0.004) and 5.05 (95% CI 1.67-
15.28, p = 0.004), respectively. In addition, patients without
any adjuvant treatment were at significantly higher risk for
local failure, compared with patients with adjuvant CT
(HR, 2.98; p = 0.07) or CRT (HR, 5.88; p = 0.007).
Table 1 Demographic characteristics and different outcomes of patients with pT1-2 node-positive rectal cancer
Characteristics No. (%)n = 219
5 y LR rate
(%) P value
5 y DM rate
(%)
P
value
5 y DFS rate
(%)
P
value
5 y OS rate
(%) P value
Gender
Male 116 (53.0) 16.6
0.095
38.4
0.305
57.6
0.162
72.4
0.428
Female 103 (47.0) 8.1 28.5 69.1 81.0
Age
<60 130 (59.4) 13.6
0.618
26.7
0.754
70.4
0.589
81.9
0.378
≥60 89 (40.6) 10.7 42.8 53.5 70.2
Tumor Location*
Low 155 (70.8) 15.2
0.072
34.1
0.495
61.9
0.976
74.8
0.919
High-Medium 64 (29.2) 6.1 31.5 66.8 80.6
CEA(ng/ul)
<5 147 (67.1) 12.9
0.964
33.3
0.784
63.5
0.828
76.0
0.384
≥5 72 (32.9) 12.0 34.7 61.8 74.6
Tumor Size
<3.5 100 (45.7) 13.0
0.935
30.3
0.346
66.8
0.423
73.7
0.898
≥3.5 119 (54.3) 12.1 35.6 60.8 77.8
Surgery**
AR 114 (52.1) 4.8
0.002
29.9
0.423
69.0
0.621
81.3
0.782
APR 105 (47.9) 19.9 34.2 59.6 73.3
Histopathology
Adenocarcinoma 200 (91.3) 11.9
0.510
32.6
0.931
64.2
0.522
76.9
0.681Mucinous
Cancer
19 (8.7) 17.1 33.7 59.9 75.1
Tumor Grade
High 30 (13.7) 12.9
0.978
42.6
0.684
54.5
0.856
67.9
0.912
Low-Medium 189 (86.3) 12.5 31.8 64.5 77.7
T Stage
T1 61 (27.9) 6.9
0.202
43.1
0.145
57.8
0.746
81.1
0.832
T2 158 (72.1) 14.3 29.9 64.9 76.1
N Stage
N1 162 (74.0) 8.7
0.007
27.6
0.012
70.4
0.001
81.8
0.002
N2 57 (26.0) 23.0 49.9 43.9 62.5
Sampled Lymph
Nodes
<12 106 (48.4) 9.8
0.291
35.2
0.509
61.8
0.927
77.5
0.864
≥12 113 (51.6) 15.5 31.0 64.9 76.3
PNI/LVI
No 148 (67.6) 9.7
0.144
28.9
0.028
68.1
0.043
78.3
0.705
Yes 71 (32.4) 18.7 41.6 53.7 73.2
Adjuvant Treatment
No 49 (22.4) 23.5
0.131
49.5
0.384
48.2
0.930
82.1
0.685Adjuvant CT 98 (44.7) 11.2 25.8 69.1 80.5
Adjuvant CRT 72 (32.9) 7.5 42.4 56.5 61.3
*Tumor location: Low, within 6 cm from anal verge; High-Medium, from 6 to 15 cm from anal verge.
**Abbreviations: AR Anterior Resection, APR Abdominoperineal Resection, CT Chemotherapy, CRT Chemoradiotherapy, PNI perineural invasion, LVI lymphovascular
invasion.
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Figure 1 The LR rates in all patients with different adjuvant treatment modalities.
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Further analyses were performed to assess the importance
of different adjuvant treatments for patients’ outcomes. In
our series, more patients with high-grade tumors, perineu-
ral or lymphovascular invasion received adjuvant CRTTable 2 The distribution of main clinicopathological characte
Treatment information No adjuvant (%) n = 49
Tumor Size
<3.5 22 (10.0)
≥3.5 27 (12.3)
Surgery
AR 29 (13.2)
APR 20 (9.1)
Histopathology
Adenocarcinoma 44 (20.1)
Mucinous Cancer 5 (2.3)
Tumor Grade
High 6 (2.7)
Low-Medium 43 (19.6)
T Stage
T1 10 (4.6)
T2 39 (17.8)
N Stage
N1 35 (16.0)
N2 14 (6.4)
PNI/LVI
No 33 (15.1)
Yes 16 (7.3)(Table 2). The distributions of adjuvant treatments were
comparable among different N stage, T stage and type of
surgery. The interaction of treatment modalities and pa-
tients’ outcomes was presented in Table 3. No statistical
significance was found by comparing outcomes in patientsristics among different treatment modalities
Adjuvant CT (%) n = 98 Adjuvant CRT (%) n = 72 P value
42 (19.2) 36 (16.4)
0.65
56 (25.6) 36 (16.4)
49 (22.4) 36 (16.4)
0.53
49 (22.4) 36 (16.4)
90 (41.1) 66 (30.1)
0.91
8 (3.7) 6 (2.7)
7 (3.2) 17 (7.8)
0.008
91 (41.6) 55 (25.1)
28 (12.8) 23 (10.5)
0.37
70 (32.0) 49 (22.4)
78 (35.6) 49 (22.4)
0.21
20 (9.1) 23 (10.5)
76 (34.7) 39 (17.8)
0.006
22 (10.0) 33 (15.1)
Table 3 The outcomes and interaction of patients with different treatment modalities
5 y LR rate 5 y DM rate 5 y DFS rate 5 y OS rate
No adjuvant treatment vs. Any adjuvant Treatment (n = 219)
No Adjuvant Treatment (n = 49) 23.5* 49.5 48.2 82.1
Any Adjuvant Treatment (n = 170) 9.5 31 65.6 75.5
No adjuvant CRT vs. Adjuvant CRT (n = 219)
No adjuvant CRT (n = 147) 15 29.1 65.9 81.3
Adjuvant CRT (n = 72) 7.5 43.4 56.5 61.3
No adjuvant CT vs. Adjvuant CT only (n = 147)
No adjuvant CT (n = 49) 23.5 49.5 48.2 82.1
Adjuvant CT only (n = 98) 11.2 25.8 69.1 80.5
*None of the outcomes in this table had statistical significance.
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no adjuvant CRT vs. adjuvant CRT, and no adjuvant treat-
ment vs. adjuvant chemotherapy only.
By re-categorizing patients by more detailed TN stage,
significantly different outcomes (5-year LR, DM, DFS
and OS rates) were observed among patients with T1N1,
T2N1, T1N2 and T2N2 disease (Table 4). Therefore, in our
series, patients with T1-2 node-positive rectal cancer could
be divided into three risk subsets with significantly differ-
ent LR rates: Low-risk, T1N1; Intermediate-risk, T2N1 and
T1N2; and High-risk, T2N2 (p = 0.005, Figure 2). In Low-
risk patients, the 5-year LR rate was only 5.3%, while the
5-year DM rate was 22.9%. In High-risk patients, both the
5-year LR rate and DM rates were as high at 26.4% and
50.6%, respectively, with a significantly lower 5-year OS
rate (59.3%, vs. 82.5% for Low-risk).
Among the 42 High-risk patients, 14 patients (33.3%) re-
ceived adjuvant radiotherapy, while the other 28 patients
received no adjuvant treatment or adjuvant chemotherapy
alone. Only one of the 14 radiated patients experienced a
local recurrence for a 5-year LR rate of 9.1%, while 9 of
the 28 non-radiated patients experience local recurrence
for a 5-year LR rate of 34.8% (Figure 3). A trend was ob-
served favoring adjuvant radiation for patients with T2N2
rectal cancer (p = 0.08).
Discussion
The management of rectal cancer requires a multidisciplin-
ary team approach and individualized treatment based onTable 4 Outcomes of patients with rectal cancer in
detailed TN stage
Detailed TN
stage
T1N1 T2N1 T1N2 T2N2
P value
n = 46 n = 15 n = 116 n = 42
5 y LR rate (%) 5.3 9.7 12.5 26.4 0.014
5 y DM rate (%) 22.9 42.3 38.1 50.6 0.025
5 y DFS rate (%) 73.8 58.8 61.9 41.0 0.004
5 y OS rate (%) 82.5 82.2 77.1 59.3 0.011assessment of tumor stage, location and surgical resectabil-
ity. Although preoperative locoregional staging is standard
for all patients with rectal cancer, the currently accepted
methods, pelvic MRI and EUS, are imperfect, particularly
for lymph node staging [9-13]. Retrospective studies have
demonstrated a relatively lower risk of lymph node metas-
tasis in T1-2 rectal cancers, compared with T3 tumors
[14-18]. Therefore, most patients with clinically staged T1-
2 node-negative rectal cancer will undergo primary resec-
tion, and adjuvant treatment will be determined according
to the pathological stage. For the small subset of patients
with pT1-2 node-positive rectal cancer, the optimal com-
bination of surgery, chemotherapy and radiotherapy is still
controversial. Based on outcomes data, adjuvant chemo-
therapy is recommended for all patients with node-positive
rectal cancer [19,20]. Consistent with this recommenda-
tion, in our series, the 5-year DM rate for patients with
pT1-2 node-positive rectal cancers who received adjuvant
chemotherapy was 25.8%, which was obviously lower than
patients without any adjuvant therapy (5-year DM rate,
49.5%).
We sought to determine whether or not adjuvant
radiotherapy improves local control following an optimal
surgery. An optimal TME for T1-2 tumors can success-
fully resect the primary tumor, dissect the perirectal
fascia and clear any involved lymph nodes [21-23]. In
our series, local control was similar between patients
who did or did not receive adjuvant radiotherapy. By
analyzing the patients within more detailed TN stage
subsets, we found that the 5-year LR rate was 26.4% for
patients with pT2N2 rectal cancer, which was almost five
times that with pT1N1 tumors (5.3%). Of all the 46 pa-
tients with pT1N1 tumors, there were only 2 cases of
local recurrence. Although it is difficult to provide a per-
suasive conclusion, the optimal local control suggested
obviating radiotherapy may be reasonable in pT1N1 pa-
tients. However, for 42 patients with pT2N2 tumors, al-
though in a small number of cases, local recurrence rate
was greatly reduced by adjuvant CRT, which suggested
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Figure 2 The LR rates for patients within different risk groups.
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our data indicate that adjuvant CRT is warranted for pa-
tients with pT2N2 rectal cancer.
Unlike with colon cancer, prevention of local recurrence
is a major concern in treatment decision making for rectal
cancer. It is difficult to define the risk of local recurrence
according to the TNM stage. In a pooled analysis of three
North American randomized phase III rectal adjuvant tri-
als, patients were categorized into three groups with dis-
tinct DFS and OS [4,24-26]. Because all patients receivedMo
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Figure 3 The LR rates for high-risk patients with or without postoperpostoperative radiotherapy, it was impossible to compare
local control with or without radiotherapy. Only a 2% dif-
ference in local control was observed for patients with
pT1-2 N1 tumors vs. pT1-2 N2 tumors. Data from an add-
itional two randomized phase III North American rectal
cancer adjuvant studies [26,27] was added to allow for a
comparison of outcomes following multiple treatment mo-
dalities (surgery alone, surgery + radiotherapy, surgery +
CRT and surgery + CT) [28]. In this analysis, patients with
pT1-2 N1 and pT1-2 N2 tumors experienced similarnths
12010896847260
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ment. Patients with pT1 and pT2 tumors were combined
when comparing outcomes. By contrast, our study showed
that distinct LR and DM rates exist among patients with
pT1 and pT2 node-positive rectal cancers. To improve
local control and minimize potential harm from overtreat-
ment, adjuvant therapy should be individualized for these
subsets of patients.
We were unable to determine whether adjuvant CRT
is warranted in patients with Intermediate-risk (pT1N2
and pT2N1) rectal cancer. Although it might be possible
to improve the 5-year LR rate to less than 10%, we be-
lieve that over 35% 5-year DM rate should prioritize
combination chemotherapy in this patient subgroup. It
is important for physicians to assess the tolerability of
adjuvant CT only or CRT in advance. For patients of
intermediate risk, it may be beneficial to consider adding
radiotherapy to adjuvant treatment if combined chemo-
therapy was well tolerated.
T1-2 rectal cancer is generally considered to be a local
disease that is unlikely to result in regional or distant
metastasis. The intrinsic cause of metastasis in T1-2 rec-
tal cancer is unknown. The tumor invasion depth (T2
vs. T1), or submucosal invasion in T1 patients (sm1-3)
may not correlate with lymph node metastasis [15,29].
Of note, 53% of patients in our study had T1N2 disease.
Some studies have found that markers of aggressiveness,
vascular invasion or tumor grade, associate with early
lymph node metastasis [5,30,31]. Further study of the
biological features of these cases may improve our un-
derstanding of invasion by rectal cancer cells.
Conclusions
In our study, we provide the detailed outcomes and pre-
liminary survival analysis in a relatively infrequent subset
of rectal cancer. Patients with T1-2 node-positive rectal
cancer can be classified into three risk subsets based on
local control rates. Great treatment disparities exist in
pT1-2 node positive rectal cancer. Postoperative treat-
ment needs to be individualized for these patients. This
retrospective analysis suggests adjuvant CRT may be
warranted in patients with pT2N2 rectal cancer, while
the benefit in patients with pT1N1 rectal cancer was still
undetermined.
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